These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16463404)

  • 1. Approval process and access to prescription drugs in Canada.
    Marra CA; Lynd LD; Anis AH; Esdaile JM
    Arthritis Rheum; 2006 Feb; 55(1):9-11. PubMed ID: 16463404
    [No Abstract]   [Full Text] [Related]  

  • 2. "New approach" as Health Canada seeks conditional licences for drugs, new pediatric office.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):864. PubMed ID: 15743911
    [No Abstract]   [Full Text] [Related]  

  • 3. Health Canada proposes new regulatory regime for drugs.
    Kondro W
    CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription drugs are the biggest bargain in health care, and all Americans should have access to them.
    Holmer AF
    Md Med; 2003; 4(2):48-9. PubMed ID: 12847830
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription drug approval in Canada: a risk-benefit analysis.
    Davis T
    J Can Dent Assoc; 1995 Jul; 61(7):578-9. PubMed ID: 7627885
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing prescription medications for priority regulatory review.
    Rawson NS
    Regul Toxicol Pharmacol; 2005 Jun; 42(1):70-6. PubMed ID: 15896445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An interview with Actuary Juan Antonio Fernández Ortiz, National Comissioner of Health Social Protection].
    Fernández Ortiz JA
    Salud Publica Mex; 2004; 46(6):594-6. PubMed ID: 15624864
    [No Abstract]   [Full Text] [Related]  

  • 8. [Children of the North--a national priority of Russia].
    Zaĭdfudim PKh
    Med Parazitol (Mosk); 1998; (3):7-9. PubMed ID: 9791997
    [No Abstract]   [Full Text] [Related]  

  • 9. [Model project will separate chaff from wheat. Phytopharmaceutical prescription--without fear of censure].
    Glaeske G
    MMW Fortschr Med; 2000 Mar; 142(11):51-2. PubMed ID: 10786092
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada.
    Sarma S; Basu K; Gupta A
    Soc Sci Med; 2007 Dec; 65(12):2553-65. PubMed ID: 17761377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The federal targetted programs Children of the North and Children of Refugee Families and of Forced Migrants. Their structure and tasks].
    Onishchenko GG; Khalilullina AS
    Med Parazitol (Mosk); 1998; (3):3-6. PubMed ID: 9791996
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the trade-offs of the Canadian health system.
    Halvorson GC
    Healthc Financ Manage; 2007 Oct; 61(10):82-4. PubMed ID: 17953187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 14. A decade of the Fast Track programme.
    Reichert JM; Rochon SL; Zhang BD
    Nat Rev Drug Discov; 2008 Nov; 7(11):885-6. PubMed ID: 18948998
    [No Abstract]   [Full Text] [Related]  

  • 15. [An interview of Salud Pública de México with Doctor Julio Frenk Mora, Ministry of Health of Mexico].
    Frenk Mora J
    Salud Publica Mex; 2004; 46(6):588-94. PubMed ID: 15624863
    [No Abstract]   [Full Text] [Related]  

  • 16. Health minister ends special access to prescription heroin.
    Eggertson L
    CMAJ; 2013 Nov; 185(17):E773-4. PubMed ID: 24130238
    [No Abstract]   [Full Text] [Related]  

  • 17. Report calls for major changes in drug-approval process, but will they be implemented?
    Robinson A
    CMAJ; 1993 Feb; 148(3):432-5. PubMed ID: 8439917
    [No Abstract]   [Full Text] [Related]  

  • 18. [The benefit provided by new medicinal products in 2005-2006--the viewpoint of the French National Authority for Health].
    Bouvenot G
    Therapie; 2007; 62(5):387-91. PubMed ID: 18206101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
    Schmidt K
    MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.